期刊文献+

磁共振成像评价乳腺癌治疗相关心肌损伤的研究进展 被引量:3

Research progress on the evaluation of cardiac dysfunction post breast cancer therapy by magnetic resonance examination
原文传递
导出
摘要 乳腺癌是女性发病率及死亡率最高的恶性肿瘤,随着早期诊断及治疗水平的提高,患者生存期延长,化学治疗、人表皮生长因子受体2分子靶向治疗及放射治疗相关心肌损伤越来越受到重视。心脏磁共振成像(CMR)是评估心脏结构及功能的金标准,能够在体识别心肌组织学改变,为抗肿瘤治疗相关心肌损伤监测及诊断提供准确信息。该文就CMR评价乳腺癌治疗相关心肌损伤的研究进展做一综述。
作者 程赛楠 张红梅 赵心明 Cheng Sainan;Zhang Hongmei;Zhao Xinming(Department of Radiology,National Cancer Center,National Clinical Research Center for Cancer,Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2020年第11期985-989,共5页 Chinese Journal of Cardiology
  • 相关文献

参考文献2

二级参考文献30

  • 1Wolff AC, Hammond MEH,Hicks DG, et al. Recommendationsfor human epidermal growth factor receptor 2 testing in breastcancer: American Society of Clinical Oncology/College ofAmerican Pathologists clinical practice guideline update. ArchPathol Lab Med, 2013,138(2) : 241-256. DOI: 10. 5858/arpa.2013-0953-SA.
  • 2Fabi A, Di Benedetto A, Metro G,et al. HER2 protein and genevariation between primary and metastaticbreast cancer :significance and impact on patient care. Clin Cancer Res, 2011,17(7) : 2055-2064. DOI: 10.1158/1078-0432. CCR-10-1920.
  • 3Robert N,Leylan-Jones B, Asmar L, et al. Randomized phase Idstudy of trastuzumab, paclitaxel, and carboplatin compared withtrastuzumab and paclitaxel in women with HER-2 -overexpressingmetastatic breast cancer[ J]. J Clin Oncol, 2006, 24(18) : 2786-2792.
  • 4Wardley AM, Pivot X,Morales-Vasquez F, et al. Randomizedphase II trial of first-line trastuzumab plus docetaxel andcapecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer [ J ]. J Clin Oncol,2010,28(6): 976-983. DOI: 10.1200/JC0.2008.21.6531.
  • 5Andersson M, Lidbrink E, Bjerre K, et al. Phase HI randomizedstudy comparing docetaxel plus trastuzumab with vinorelbine plustrastuzumab as first-line therapy of metastatic or locally advancedhuman epidermal growth factor receptor 2-positive breast cancer:The HERNATA study [J]. J Clin Oncol, 2011, 29 ( 3 ) : 264-271. DOI: 10.12OO/JCO. 2010. 30. 8213.
  • 6Schaller G, Fuchs I, Gonsch T,et al. Phase U Study ofCapecitabine Plus Trastuzumab in Human Epidermal GrowthFactor Receptor 2 -Overexpressing Metastatic Breast CancerPretreated With Anthracyclines or Taxanes [ J ]. J Clin Oncol,2007, 25(22) : 3246-3250.
  • 7Yardley DA, Burris HA, Hanson S, et al. Weekly gemcitabineand trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer[ J]. Clin Breast Cancer,2009 , 9(3) : 178-183. DOI: 10.3816/CBC.2009. n. 029.
  • 8Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab,and docetaxel in HER2-positive metastatic breast cancer [ J ] . NEngl J Med, 2015,372 ( 8 ) : 724-734. DOI: 10. 1056/NEJMoal413513.
  • 9Kaufman B, Mackey JR,Clemens MR,et al. Trastuzumab plusanastrozole versus anastrozole alone for the treatment ofpostmenopausal women with human epidermal growth factorreceptor 2-positive, hormone receptor-positive metastatic breastcancer : Results from the randomized phase ]H TAnDEM study[J]. J Clin Oncol, 2009, 27(33) : 5529-5537. DOI: 10. 1200/JCO.2008.20.6847.
  • 10Johnston S, Pippen J, Pivot X, et al. Lapatinib combined withletrozole versus letrozole and placebo as first-line therapy forpostmenopausal hormone receptor-positive metastatic breast cancer[J]. J Clin Oncol, 2009, 27(33) : 5538-5546. 10.1200/jc0.2009.23.3734.

共引文献78

同被引文献33

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部